RPG Life Sciences Ltd: Pharma Ka RPG—Rocket, Profit, Growth?
1. At a Glance
RPG Life Sciences is part of the RPG Group and operates in formulations and active pharma ingredients (APIs). With a debt-free balance sheet, expanding margins, and a tasty ₹24 dividend, this pharma midcap has gone from boring to blazing—up 4.7x in 5 years.
2. Introduction with Hook
Imagine if Parle-G biscuits suddenly turned into Ferrero Rocher—same brand, new avatar. That’s RPG Life Sciences. Once a sleepy division of RPG Group, now a fire-breathing margin monster in the pharma space.
Stock CAGR: 53% in 5 years, 63% in 3 years
ROCE: 33% in FY25
FY25 Net Profit: ₹183 Cr (up 108% YoY thanks to a cheeky ₹83 Cr land sale gain)
But… was the growth organic or just a lucky land flip? Let’s find out.
3. Business Model (WTF Do They Even Do?)
RPG Life Sciences has three verticals:
Domestic Formulations (Branded) – Prescription meds in nephrology, immunology, gastro, and cardiac
International Formulations (Generics) – Exports to regulated markets (EU, UK, Australia)
APIs (Active Pharma Ingredients) – Backward integrated into their own formulations; margin booster.
They’re present in 21 countries, 90% products are vertically integrated, and they’ve slowly migrated from plain-vanilla generics to premium branded therapies.
